[go: up one dir, main page]

ES2096577T3 - Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar. - Google Patents

Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar.

Info

Publication number
ES2096577T3
ES2096577T3 ES90201054T ES90201054T ES2096577T3 ES 2096577 T3 ES2096577 T3 ES 2096577T3 ES 90201054 T ES90201054 T ES 90201054T ES 90201054 T ES90201054 T ES 90201054T ES 2096577 T3 ES2096577 T3 ES 2096577T3
Authority
ES
Spain
Prior art keywords
retinoid
cetoconazole
treatment
acne
vulgar acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90201054T
Other languages
English (en)
Inventor
Gerard Frans Maria Cauwenbergh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2096577T3 publication Critical patent/ES2096577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

EL USO DE QUETACONAZOLA O UNA SAL ACIDA FARMACEUTICAMENTE ACEPTABLE DE LA MISMA SE EMPLEA PARA LA FABRICACION DE UN MEDICAMENTO PARA TRATAR DE FORMA TOPICA A SUJETOS QUE SUFREN DE ACNE, LA COMPOSICION COMPRENDE QUETACONAZOLA Y UN RETINOIDE.
ES90201054T 1989-05-03 1990-04-26 Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar. Expired - Lifetime ES2096577T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898910069A GB8910069D0 (en) 1989-05-03 1989-05-03 Method of topically treating acne vulgaris

Publications (1)

Publication Number Publication Date
ES2096577T3 true ES2096577T3 (es) 1997-03-16

Family

ID=10656092

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90201054T Expired - Lifetime ES2096577T3 (es) 1989-05-03 1990-04-26 Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar.

Country Status (16)

Country Link
EP (1) EP0396184B1 (es)
JP (1) JP2833711B2 (es)
KR (1) KR0161526B1 (es)
AT (1) ATE145136T1 (es)
AU (1) AU626672B2 (es)
CA (1) CA2015838C (es)
DE (1) DE69029100T2 (es)
DK (1) DK0396184T3 (es)
ES (1) ES2096577T3 (es)
GB (1) GB8910069D0 (es)
GR (1) GR3022519T3 (es)
IE (1) IE74192B1 (es)
IL (1) IL94267A (es)
PT (1) PT93935B (es)
SG (1) SG47035A1 (es)
ZA (1) ZA903339B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583136A (en) * 1990-01-29 1996-12-10 Johnson & Johnson Consumer Products, Inc. Retinoid containing skin care compositions containing imidazoles
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
LU87843A1 (fr) * 1990-11-15 1992-08-25 Cird Galderma Gel aqueux a base d'acide retinoique et d'hydroxypropyl-beta-cyclodextrine et son utilisation en medecine humaine et en cosmetique
GR1002207B (en) * 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
WO1994014447A1 (en) * 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
ES2064288B1 (es) * 1993-07-06 1995-08-01 Ornosa Enrique Viayna Composicion para el tratamiento de afecciones cutaneas, su preparacion y su uso.
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US6150403A (en) * 1997-10-14 2000-11-21 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
KR100247558B1 (ko) * 1997-11-24 2000-05-01 김충섭 사이클로덱스트린을 이용한 이온토포레시스 개선방법
RU2120305C1 (ru) * 1997-11-27 1998-10-20 Открытое акционерное общество Химико-фармацевтический комбинат "Акрихин" Фармацевтический состав, обладающий противогрибковой активностью, и способ его получения
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
GB2365770B (en) * 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
DE10131796A1 (de) * 2001-06-30 2003-01-16 Beiersdorf Ag Verwendung von Cardiolipin in kosmetischen oder dermatologischen Zubereitungen
DE10151245A1 (de) * 2001-10-17 2003-05-15 Beiersdorf Ag Kosmetische und/oder dermatologische Wirkstoffkombination
KR100432449B1 (ko) * 2001-11-30 2004-05-22 우원홍 케토코나졸 함유 피부 미백용 외용제 조성물
FR2835434B1 (fr) * 2002-02-01 2006-03-03 Lvmh Rech Utilisation cosmetique ou dermatologique de la vitamine a ou de ses esters, en association avec une beta-cyclodextrine partiellement methylee
EP2005954B8 (en) * 2006-03-23 2012-11-28 TMRC Co., Ltd. Kit for cancer therapy and pharmaceutical composition for cancer therapy
WO2013107809A1 (en) * 2012-01-19 2013-07-25 Merz Pharma Gmbh & Co. Kgaa Use of azole antifungals for the treatment of actinic keratosis
CN108066342A (zh) * 2016-11-17 2018-05-25 江苏灵豹药业股份有限公司 一种复方酮康唑乳膏剂及其制备方法
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
GB2068228B (en) * 1980-01-24 1984-02-29 Janssen Pharmaceutica Nv Anti-microbial compositions for the topical treatment of acne vulgaris
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
GB2097783B (en) * 1981-04-23 1984-12-12 Dermal Lab Ltd Imidazoles
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients

Also Published As

Publication number Publication date
DE69029100T2 (de) 1997-04-03
KR0161526B1 (ko) 1998-12-01
IE901607L (en) 1990-11-03
EP0396184A3 (en) 1992-05-20
CA2015838A1 (en) 1990-11-03
JPH02295927A (ja) 1990-12-06
ATE145136T1 (de) 1996-11-15
AU626672B2 (en) 1992-08-06
CA2015838C (en) 2002-08-27
ZA903339B (en) 1992-01-29
IE74192B1 (en) 1997-07-16
PT93935B (pt) 1996-11-29
JP2833711B2 (ja) 1998-12-09
AU5471190A (en) 1990-11-15
KR900017590A (ko) 1990-12-19
IL94267A0 (en) 1991-03-10
GB8910069D0 (en) 1989-06-21
GR3022519T3 (en) 1997-05-31
IL94267A (en) 1994-11-11
PT93935A (pt) 1991-02-08
EP0396184A2 (en) 1990-11-07
DE69029100D1 (de) 1996-12-19
SG47035A1 (en) 1998-03-20
EP0396184B1 (en) 1996-11-13
DK0396184T3 (da) 1996-12-30

Similar Documents

Publication Publication Date Title
ES2096577T3 (es) Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar.
EG20273A (en) Process for preparing of pyrazolopyrimidines and their use in the treatment of stress related and other diseases
ATE231885T1 (de) Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ES2090317T3 (es) Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
AU1976183A (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69129693D1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
IE870577L (en) Topical amide preparation
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
HU896587D0 (en) 2-amino-carbonic acid derivatives, and medical preparations containing them as active agents, and process for the production of the active agents and the preparation
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
HUT60431A (en) Process for producing pharmaceutical compositions comprising naphthoquinone derivative and suitable for treating cryptosporidiosis
IT1265649B1 (it) Prodotto dermatologico per uso topico, relativo processo di produzione ed ulizzazione terapeutica nelle ustioni e patologie cutanee.
FR2341309A1 (fr) Medicament utilisable notamment pour le traitement d'affections dermatologiques, et plus particulierement du psoriasis
DE69715227D1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit
FR2167376A1 (en) Aqs, solubilized essential oils - for treating dermatological disorders
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита
ES2056804T3 (es) Utilizacion de proteina reguladora procedente de foliculos para la elaboracion de un agente terapeutico para el tratamiento del neoplasma de origen gonadal.
UA8280A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 396184

Country of ref document: ES